SGMT Stock Summary and Trading Ideas (Sagimet Biosciences - Series A | NASDAQ:SGMT)

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences - Series A trades on the NASDAQ stock market under the symbol SGMT.

As of December 19, 2025, SGMT stock price climbed to $6.28 with 978,258 million shares trading.

SGMT has a beta of 3.09, meaning it tends to be more sensitive to market movements. SGMT has a correlation of 0.24 to the broad based SPY ETF.

SGMT has a market cap of $204.24 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that SGMT belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAS.

SGMT has outperformed the market in the last year with a return of +23.9%, while the SPY ETF gained +18.1%. However, in the most recent history, SGMT shares have underperformed the stock market with its stock returning -3.7% in the last 3 month period and -1.7% for the last 2 week period, while SPY has returned +2.8% and -0.5%, respectively.

SGMT support price is $5.61 and resistance is $6.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMT shares will trade within this expected range on the day.